Siphepho Phumelele Yvonne, Liu Yi-Ting, Shabangu Ciniso Sylvester, Huang Jee-Fu, Huang Chung-Feng, Yeh Ming-Lun, Yu Ming-Lung, Wang Shu-Chi
Program in Tropical Medicine, Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Center for Cancer Research, Center for Liquid Biopsy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Biomedicines. 2021 Oct 17;9(10):1491. doi: 10.3390/biomedicines9101491.
Metabolic derangement is characteristic in patients with hepatitis C virus (HCV) infection. Aside from established liver injury, various extrahepatic metabolic disorders impact the natural history of the disease, clinical outcomes, and the efficacy of antiviral therapy. The presence of steatosis, recently redefined as metabolic-associated fatty liver disease (MAFLD), is a common feature in HCV-infected patients, induced by host and/or viral factors. Most chronic HCV-infected (CHC) patients have mild steatosis within the periportal region of the liver with an estimated prevalence of 40% to 86%. Indeed, this is higher than the 19% to 50% prevalence observed in patients with other chronic liver diseases such as chronic hepatitis B (CHB). The histological manifestations of HCV infection are frequently observed in genotype 3 (G-3), where relative to other genotypes, the prevalence and severity of steatosis is also increased. Steatosis may independently influence the treatment efficacy of either interferon-based or interferon-free antiviral regimens. This review aimed to provide updated evidence of the prevalence and risk factors behind HCV-associated steatosis, as well as explore the impact of steatosis on HCV-related outcomes.
丙型肝炎病毒（HCV）感染患者具有代谢紊乱的特征。除了已确定的肝损伤外，各种肝外代谢紊乱会影响疾病的自然史、临床结局以及抗病毒治疗的疗效。脂肪变性的存在，最近被重新定义为代谢相关脂肪性肝病（MAFLD），是HCV感染患者的常见特征，由宿主和/或病毒因素引起。大多数慢性HCV感染（CHC）患者在肝脏门周区域有轻度脂肪变性，估计患病率为40%至86%。事实上，这一比例高于在其他慢性肝病如慢性乙型肝炎（CHB）患者中观察到的19%至50%的患病率。HCV感染的组织学表现常见于3型（G-3），相对于其他基因型，脂肪变性的患病率和严重程度也有所增加。脂肪变性可能独立影响基于干扰素或无干扰素的抗病毒方案的治疗效果。本综述旨在提供关于HCV相关脂肪变性患病率和危险因素的最新证据，并探讨脂肪变性对HCV相关结局的影响。
